Science Park
2 Snunit St. POB 455
Karmiel 2161401
Israel
972 4 902 8100
https://www.protalix.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 208
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Dror Bashan | President, CEO & Director | 473.16k | N/D | 1967 |
Mr. Eyal Rubin M.B.A. | Senior VP, CFO, Treasurer & Corporate Secretary | 813.73k | N/D | 1976 |
Mr. Yaron Naos | Senior Vice President of Operations | 409.95k | N/D | 1964 |
Ms. Yael Fellous | Vice President of Human Resources | N/D | N/D | N/D |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
La calificación ISS Governance QuickScore de Protalix BioTherapeutics, Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 3; Junta: 8; Derechos del accionista: 1; Compensación: 8.